MedTrace Logo

Levocetirizine 5 mg: Reduction of Symptoms, Airway Resistance and Sleep Impairment in Persistent Allergic Rhinitis

NCT00355771 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2008-01-15

No results posted yet for this study

Summary

The purpose of this study is to investigate, whether levocetirizine 5 mg relieves nasal and ocular symptoms of persistent allergic rhinitis and reduces increased airway resistance and sleep impairment due to this condition.

Conditions

  • Allergic Rhinitis

Interventions

DRUG

Levocetirizine

Intake of 1 tablet of Levocetirizine 5mg OD for 8 weeks

DRUG

Placebo

1 tablet OD in the morning for 8 weeks

Sponsors & Collaborators

  • UCB Pharma

    collaborator INDUSTRY

  • Institut für Atemwegsforschung GmbH

    lead INDUSTRY

Principal Investigators

  • Claus Bachert, MD, PhD · Institut für Atemwegsforschung

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2007-11-30
Completion
2007-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00355771 on ClinicalTrials.gov